{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000000", "text": "# ACR Appropriateness Criteria", "section": "ACR Appropriateness Criteria", "page_from": null, "page_to": null, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "775be40554cc51f8e210068b638db8646f84ef445405248945ef9834793132ca"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000001", "text": "Revised 2025\nACR Appropriateness Criteria®\n1\nStaging and Follow-up of Ovarian Cancer\nAmerican College of Radiology\nACR Appropriateness Criteria®\nStaging and Follow-up of Ovarian Cancer\nVariant 1:\nAdult. Ovarian cancer. Pretreatment staging.\nProcedure\nAppropriateness Category\nRelative Radiation Level\nCT abdomen and pelvis with IV contrast\nUsually Appropriate\n☢☢☢\nCT chest with IV contrast\nUsually Appropriate\n☢☢☢\nMRI abdomen and pelvis without and with IV\ncontrast\nMay Be Appropriate\nO\nMRI abdomen and pelvis without IV contrast\nMay Be Appropriate\nO\nCT abdomen and pelvis without IV contrast\nMay Be Appropriate\n☢☢☢\nCT chest without IV contrast\nMay Be Appropriate\n☢☢☢\nFDG-PET/MRI skull base to mid-thigh\nMay Be Appropriate\n☢☢☢\nFDG-PET/CT skull base to mid-thigh\nMay Be Appropriate\n☢☢☢☢\nUS abdomen and pelvis transabdominal\nUsually Not Appropriate\nO\nUS pelvis transvaginal\nUsually Not Appropriate\nO\nCT chest without and with IV contrast\nUsually Not Appropriate\n☢☢☢\nCT abdomen and pelvis without and with IV\ncontrast\nUsually Not Appropriate\n☢☢☢☢\nVariant 2:\nAdult. Ovarian cancer. Posttreatment response evaluation.\nProcedure\nAppropriateness Category\nRelative Radiation Level", "section": "Revised 2025", "page_from": 1, "page_to": 1, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "fb19a72bf345f3d34e3aefc62859e2ce8d5dc07d310751d8127b64bf5956f010"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000002", "text": "contrast\nUsually Not Appropriate\n☢☢☢☢\nVariant 2:\nAdult. Ovarian cancer. Posttreatment response evaluation.\nProcedure\nAppropriateness Category\nRelative Radiation Level\nCT abdomen and pelvis with IV contrast\nUsually Appropriate\n☢☢☢\nCT chest with IV contrast\nUsually Appropriate\n☢☢☢\nFDG-PET/CT skull base to mid-thigh\nUsually Appropriate\n☢☢☢☢\nMRI abdomen and pelvis without and with IV\ncontrast\nMay Be Appropriate\nO\nMRI abdomen and pelvis without IV contrast\nMay Be Appropriate\nO\nCT abdomen and pelvis without IV contrast\nMay Be Appropriate\n☢☢☢\nCT chest without IV contrast\nMay Be Appropriate\n☢☢☢\nFDG-PET/MRI skull base to mid-thigh\nMay Be Appropriate\n☢☢☢\nUS abdomen and pelvis transabdominal\nUsually Not Appropriate\nO\nUS pelvis transvaginal\nUsually Not Appropriate\nO\nCT chest without and with IV contrast\nUsually Not Appropriate\n☢☢☢\nCT abdomen and pelvis without and with IV\ncontrast\nUsually Not Appropriate\n☢☢☢☢", "section": "Revised 2025", "page_from": 1, "page_to": 1, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "1623131b171261130d29386f13a4686fea45d9dc755c51d0714c16028a1425ae"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000003", "text": "ACR Appropriateness Criteria®\n2\nStaging and Follow-up of Ovarian Cancer\nVariant 3:\nAdult. Ovarian cancer. Posttreatment routine surveillance. Asymptomatic patient, no\nsuspected recurrence.\nProcedure\nAppropriateness Category\nRelative Radiation Level\nMRI abdomen and pelvis without and with IV\ncontrast\nMay Be Appropriate\nO\nMRI abdomen and pelvis without IV contrast\nMay Be Appropriate\nO\nCT abdomen and pelvis with IV contrast\nMay Be Appropriate\n☢☢☢\nCT abdomen and pelvis without IV contrast\nMay Be Appropriate\n☢☢☢\nCT chest with IV contrast\nMay Be Appropriate\n☢☢☢\nCT chest without IV contrast\nMay Be Appropriate\n☢☢☢\nFDG-PET/MRI skull base to mid-thigh\nMay Be Appropriate\n☢☢☢\nFDG-PET/CT skull base to mid-thigh\nMay Be Appropriate\n☢☢☢☢\nUS abdomen and pelvis transabdominal\nUsually Not Appropriate\nO\nUS pelvis transvaginal\nUsually Not Appropriate\nO\nCT chest without and with IV contrast\nUsually Not Appropriate\n☢☢☢\nCT abdomen and pelvis without and with IV\ncontrast\nUsually Not Appropriate\n☢☢☢☢\nVariant 4:\nAdult. Ovarian cancer. Posttreatment evaluation. Suspected or known recurrence.\nProcedure\nAppropriateness Category\nRelative Radiation Level\nCT abdomen and pelvis with IV contrast\nUsually Appropriate", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 2, "page_to": 2, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "ccd38881c6bacc5c670f93aaa55934ea07c45e0f9f83e307f91029638ea9ff78"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000004", "text": "Adult. Ovarian cancer. Posttreatment evaluation. Suspected or known recurrence.\nProcedure\nAppropriateness Category\nRelative Radiation Level\nCT abdomen and pelvis with IV contrast\nUsually Appropriate\n☢☢☢\nCT chest with IV contrast\nUsually Appropriate\n☢☢☢\nFDG-PET/CT skull base to mid-thigh\nUsually Appropriate\n☢☢☢☢\nMRI abdomen and pelvis without and with IV\ncontrast\nMay Be Appropriate\nO\nMRI abdomen and pelvis without IV contrast\nMay Be Appropriate\nO\nCT abdomen and pelvis without IV contrast\nMay Be Appropriate\n☢☢☢\nCT chest without IV contrast\nMay Be Appropriate\n☢☢☢\nFDG-PET/MRI skull base to mid-thigh\nMay Be Appropriate\n☢☢☢\nUS abdomen and pelvis transabdominal\nUsually Not Appropriate\nO\nUS pelvis transvaginal\nUsually Not Appropriate\nO\nCT chest without and with IV contrast\nUsually Not Appropriate\n☢☢☢\nCT abdomen and pelvis without and with IV\ncontrast\nUsually Not Appropriate\n☢☢☢☢", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 2, "page_to": 2, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "f934ce47c7b8c401d1ea635aacb481b80427890ef8a542bb611de4fc850ba853"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000005", "text": "ACR Appropriateness Criteria®\n3\nStaging and Follow-up of Ovarian Cancer\nSTAGING AND FOLLOW-UP OF OVARIAN CANCER\nExpert Panel on GYN and OB Imaging: Erica B. Stein, MDa; Aradhana M. Venkatesan, MDb; Esma A. Akin, MDc;\nEmily Barrows, MDd; Parul Barry, MDe; Nicole M. Hindman, MDf; Chenchan Huang, MDg;\nGaiane M. Rauch, MD, PhDh; Madeleine Sertic, MB, BChi; Krista Suarez-Weiss, MDj; Jason D. Wright, MDk;\nAshish P. Wasnik, MD.l\nSummary of Literature Review\nIntroduction/Background\nOvarian cancer remains the sixth most common cause of cancer mortality in women in the United States and is a\nleading cause of cancer mortality among patients with gynecologic malignancies [1]. Ovarian cancer can affect\nanyone who has ovaries, including cisgender females as well as transgender men and nonbinary gender–identifying\ngroups who have ovaries.\nThere are several different histopathologic subtypes of ovarian cancer, with epithelial ovarian cancer being the most\ncommon and accounting for approximately 90% of all malignant ovarian neoplasms [2]. Most of the information\nin this document regarding imaging use for staging and recurrence applies to epithelial ovarian cancers. There are", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 3, "page_to": 3, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "62fc41ce2bcc3aae54c568f709753f96a3d1a29e95e520e303ea522fefca3a41"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000006", "text": "in this document regarding imaging use for staging and recurrence applies to epithelial ovarian cancers. There are\ntwo major subtypes of epithelial ovarian cancers that are distinguished by molecular, genetic, and morphologic\ncharacteristics. Type I is the more indolent form that includes low-grade serous, low-grade endometrioid, mucinous\ntumors, and clear cell carcinomas. Type II includes aggressive neoplasms, such as high-grade serous or\nendometrioid, and undifferentiated cancer [3]. The aggressive, or type II ovarian cancers, typically present in\nadvanced stages (stage III-IV), after the disease has spread beyond the pelvis [4,5].\nThis document largely applies to staging and follow-up for type II ovarian cancers. Diagnostic imaging plays a\nmajor role in characterizing ovarian mass(es), determining presurgical disease extent, predicting tumor resectability,\nevaluating response to chemotherapy, and evaluating for posttreatment recurrence [2,5-11].\nAlthough surgical staging is the reference standard in ovarian cancer, initial management recommendations rely on\npresurgical imaging to assess disease extent. Pretreatment imaging can assess the likelihood of optimal primary", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 3, "page_to": 3, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "17ef6ece39ab48623657867586bc6479f0c66c313245a6cb5564bbaeeb7f248e"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000007", "text": "presurgical imaging to assess disease extent. Pretreatment imaging can assess the likelihood of optimal primary\ncytoreduction, which is the surgical removal of macroscopic disease but small sites of visible disease <1 cm in size\nmay remain [12]. In addition to disease extent, preoperative imaging can also identify sites of disease that are\ndeemed potentially unresectable or challenging to resect; for example, disease involving the small bowel mesentery\nor porta hepatis and suprarenal lymph node metastases [12]. If complete or optimal cytoreduction is not felt to be\nachievable, then neoadjuvant chemotherapy may be considered prior to interval debulking surgery.\nDiscussion of Procedures by Variant\nVariant 1: Adult. Ovarian cancer. Pretreatment staging.\nThe goal of imaging is to appropriately stage ovarian cancer in treatment-naive patients. Imaging plays a crucial\nrole in guiding the most appropriate therapeutic interventions, thereby optimizing patient outcomes and overall\nmanagement of the disease.\nCT Abdomen and Pelvis With IV Contrast\nContrast-enhanced CT is the most useful procedure in the preoperative evaluation of ovarian cancer [13]. It can", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 3, "page_to": 3, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "ed347864b2cbc8001de77135839941ccc9090a4bb79779c537b4e7e671ea3885"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000008", "text": "management of the disease.\nCT Abdomen and Pelvis With IV Contrast\nContrast-enhanced CT is the most useful procedure in the preoperative evaluation of ovarian cancer [13]. It can\nprovide clinically relevant information, including assessment of locoregional tumor extent and distant sites of\ndisease including peritoneum, omentum, mesentery, liver, and lymph nodes. Contrast-enhanced CT has a reported\naccuracy for ovarian cancer staging of up to 94% [14], and accurate abdominopelvic disease assessment can predict\nsuccessful surgical cytoreduction [13]. The sensitivity of CT staging varies depending on the anatomical location\n\naUniversity of Michigan Medical Center, Ann Arbor, Michigan. bPanel Chair, The University of Texas MD Anderson Cancer Center, Houston, Texas. cGeorge\nWashington University Hospital, Washington, District of Columbia; Commission on Nuclear Medicine and Molecular Imaging. dVirginia Commonwealth\nUniversity Health/Virginia Commonwealth University School of Medicine, Richmond, Virginia; American College of Obstetricians and Gynecologists.", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 3, "page_to": 3, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "e27ea2cc5f8e5f1c30d1fd070a1e99144fa03b2f32d69723cd27b551dd3c429e"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000009", "text": "University Health/Virginia Commonwealth University School of Medicine, Richmond, Virginia; American College of Obstetricians and Gynecologists.\neUniversity of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania; Commission on Radiation Oncology. fNew York University School\nof Medicine, New York, New York. gNew York University Langone Medical Center, New York, New York. hThe University of Texas MD Anderson Cancer\nCenter, Houston, Texas. iMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. jBrown University Health, Providence, Rhode\nIsland. kColumbia University Vagelos College of Physicians and Surgeons, New York, New York; Society of Gynecologic Oncology. lSpecialty Chair,\nUniversity of Michigan, Ann Arbor, Michigan.\n\nThe American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness\nCriteria through representation of such organizations on expert panels. Participation on the expert panel does not necessarily imply endorsement of the final\ndocument by individual contributors or their respective organization.\n\nReprint requests to: publications@acr.org", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 3, "page_to": 3, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "ffba4687e775ac907a1dafadd7058774c19ec029c6236062bc9ccdd91a1e11d6"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000010", "text": "ACR Appropriateness Criteria®\n4\nStaging and Follow-up of Ovarian Cancer\nbeing examined. One of the significant drawbacks of CT in staging ovarian cancer is its limited ability to\nconsistently identify tumor implants on the bowel surface, mesentery, or peritoneum that are smaller than 5 mm,\nparticularly in in the absence of ascites [6,15-17].\nThe addition of oral contrast on CT imaging, typically performed with positive oral contrast, can help differentiate\nperitoneal implants from adjacent bowel. Rectal contrast administration can increase the sensitivity in detecting\nrectosigmoid serosal implants [2].\nCT imaging can be instrumental in planning biopsies of the omentum or other abdominopelvic tumor sites when\npreoperative histology is necessary [18-21].\nCT Abdomen and Pelvis Without and With IV Contrast\nThere is no relevant literature to support the use of CT of the abdomen and pelvis without and with intravenous (IV)\ncontrast for ovarian cancer staging.\nCT Abdomen and Pelvis Without IV Contrast\nCT of the abdomen and pelvis without IV contrast can be considered in certain clinical settings but offers limited", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 4, "page_to": 4, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "15de19d53e05a354d8b027a02dcedfa281e9a08ccecd20c51ea0de8e78cd2d78"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000011", "text": "contrast for ovarian cancer staging.\nCT Abdomen and Pelvis Without IV Contrast\nCT of the abdomen and pelvis without IV contrast can be considered in certain clinical settings but offers limited\nability to identify small peritoneal or mesenteric implants or lymphadenopathy from bowel or adjacent organs.\nCT Chest With IV Contrast\nCT of the chest with IV contrast is a useful modality for detecting pulmonary metastases during the baseline staging\nof ovarian cancer. Presence of pleural metastases and pleural effusions may suggest transdiaphragmatic tumor\nspread. Presence of a moderate-to-large pleural effusion on preoperative CT is a predictor of poor posttreatment\noutcome and may impact decisions to pursue neoadjuvant chemotherapy over primary cytoreductive surgery [22].\nCT Chest Without and With IV Contrast\nThere is no relevant literature to support the use of CT of the chest without and with IV contrast for ovarian cancer\nstaging.\nCT Chest Without IV Contrast\nCT of the chest without IV contrast may be useful for staging evaluation. CT of the chest without IV contrast can\ndetect small pulmonary nodules; however, pleural metastases may be difficult to delineate without IV contrast.", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 4, "page_to": 4, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "d53f4f434aa66fbdd7f77138b90bd75ac203c91b8203f0e5f6e43197979633b6"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000012", "text": "detect small pulmonary nodules; however, pleural metastases may be difficult to delineate without IV contrast.\nFDG-PET/CT Skull Base to Mid-Thigh\nFluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET, when combined with CT, is a valuable tool for staging\nadvanced ovarian cancer. Although this modality has a limited role for locoregional staging, it is helpful in\nidentifying sites of distant metastatic disease, such as peritoneal and lymph node metastases when lesion\ncharacterization may alter clinical management. A recent meta-analysis showed no statistical difference in\nsensitivity between CT with IV contrast and FDG-PET/CT in the detection of stage III ovarian cancer; however,\nthere was improved specificity with FDG-PET/CT [23].\nFDG-PET/MRI Skull Base to Mid-Thigh\nFDG-PET, when combined with MRI, is a diagnostic alternative to more established imaging modalities, such as\ncontrast-enhanced CT and FDG-PET/CT, and may be useful for pretreatment staging. MRI allows for high contrast\nand spatial resolution of soft tissues as compared with CT, and when paired with the functional capabilities of FDG", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 4, "page_to": 4, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "eda07dfe851eaa4147fcf41aee3f7b6618e8e783d444c0276a7ba74e0fc7d367"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000013", "text": "and spatial resolution of soft tissues as compared with CT, and when paired with the functional capabilities of FDG\nit may offer improved diagnostic performance compared with FDG-PET/CT [24-26]. FDG-PET/MRI can better\nresolve sites of physiologic FDG activity in the pelvis (eg, pelvic ureters), distinguishing them from peritoneal\ndeposits, which is an advantage over FDG-PET/CT [27].\nMRI Abdomen and Pelvis Without and With IV Contrast\nMRI of the abdomen and pelvis can be used for ovarian cancer staging, specifically in certain clinical settings such\nas in patients with a history of fertility preservation for borderline tumors and/or inconclusive CT findings [28,29].\nMRI has shown similar accuracy to CT for initial staging and has been shown to predict peritoneal tumor volume\ncomparable to surgery [30,31]. Limitations in the use of MRI for ovarian cancer staging include nonroutine use of\nintraluminal gastrointestinal contrast agents and greater likelihood of patient motion due to examination length.\nMRI Abdomen and Pelvis Without IV Contrast\nMRI of the abdomen and pelvis without IV contrast has a limited role in baseline ovarian cancer staging, but it can", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 4, "page_to": 4, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "1dfe053d29a2ab7c6207dde5472712366cd9f561367674b965b2cb2307933952"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000014", "text": "MRI Abdomen and Pelvis Without IV Contrast\nMRI of the abdomen and pelvis without IV contrast has a limited role in baseline ovarian cancer staging, but it can\noffer better soft tissue resolution when compared with CT abdomen pelvis without IV contrast.", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 4, "page_to": 4, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "bc09eca5568d601de2f4dd9270605dbf7bf88a30b0ce016a28d86c7bdd999c0f"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000015", "text": "ACR Appropriateness Criteria®\n5\nStaging and Follow-up of Ovarian Cancer\nUS Abdomen and Pelvis Transabdominal\nTransabdominal ultrasound (US) of the abdomen and pelvis is not useful for pretreatment ovarian cancer staging.\nA recent meta-analysis observed that although US had a good diagnostic performance in detecting disease in certain\nanatomical sites (eg, rectosigmoid), it had low diagnostic performance in other anatomical sites (eg, root of the\nmesentery) [32]. Although few studies have shown sensitivity comparable to that of CT [33], the use of US in\novarian cancer staging does not reflect universal practice or experience. National Comprehensive Cancer Network\n(NCCN) guidelines state that in patients with newly diagnosed ovarian cancer after recent surgical procedure that\nimaging with US can be used as clinically indicated [2].\nUS Pelvis Transvaginal\nThere is no relevant literature to support the use of transvaginal pelvic US for ovarian cancer staging. Transvaginal\npelvis US is helpful to determine site of origin of a pelvic mass, characterize the lesion, and assist in image-guided\ncore biopsy [34].\nVariant 2: Adult. Ovarian cancer. Posttreatment response evaluation.", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 5, "page_to": 5, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "fb5a354b0bf282f58556a6d33ce85378bf3fc3ed291664f12d4aa8c10de127ce"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000016", "text": "core biopsy [34].\nVariant 2: Adult. Ovarian cancer. Posttreatment response evaluation.\nThe goal of imaging is to assess the posttreatment response evaluation in ovarian cancer. With the relevant imaging\ninformation, an appropriate clinical and follow-up plan can be determined.\nCT Abdomen and Pelvis With IV Contrast\nCT of the abdomen and pelvis with IV and oral contrast is the most useful procedure to assess disease extent\nfollowing treatment [35]. NCCN guidelines state that contrast-enhanced CT of the abdomen and pelvis can be\nperformed for monitoring and follow-up of tumor burden [2].\nCT Abdomen and Pelvis Without and With IV Contrast\nThere is no relevant literature to support the use of CT of the abdomen and pelvis without and with IV contrast for\nposttreatment ovarian cancer response evaluation.\nCT Abdomen and Pelvis Without IV Contrast\nCT of the abdomen and pelvis without IV contrast can be considered in certain clinical settings but offers limited\nability to identify metastases, especially differentiating small peritoneal or mesenteric implants, or\nlymphadenopathy from bowel or adjacent organs.\nCT Chest With IV Contrast", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 5, "page_to": 5, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "27bd7bf8cfc919ce40616976f70cbf96fa3ecdcfa0146d6e7e798a96e7f44a4b"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000017", "text": "ability to identify metastases, especially differentiating small peritoneal or mesenteric implants, or\nlymphadenopathy from bowel or adjacent organs.\nCT Chest With IV Contrast\nCT of the chest with IV contrast is a useful modality to assess posttreatment response in patients with ovarian cancer\n[2].\nCT Chest Without and With IV Contrast\nThere is no relevant literature to support the use of CT of the chest without and with IV contrast for posttreatment\novarian cancer response evaluation.\nCT Chest Without IV Contrast\nCT of the chest without IV contrast may be considered to assess posttreatment response. CT of the chest without\nIV contrast can detect small pulmonary nodules; however, pleural metastases may be difficult to delineate without\nIV contrast.\nFDG-PET/CT Skull Base to Mid-Thigh\nFDG-PET/CT may be useful in the posttreatment response evaluation of ovarian cancer [2]. Resolution or\nregression of neoplastic implants with concomitant reduction in metabolic activity indicates a favorable response\nto therapy.\nFDG-PET/MRI Skull Base to Mid-Thigh\nFDG-PET/MRI may be useful in the posttreatment response evaluation of ovarian cancer. In postoperative patients,", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 5, "page_to": 5, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "0e2f8eee68957d3f5294f161503a2dc15b75ca28a862b72f4168ce69a35af197"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000018", "text": "to therapy.\nFDG-PET/MRI Skull Base to Mid-Thigh\nFDG-PET/MRI may be useful in the posttreatment response evaluation of ovarian cancer. In postoperative patients,\nFDG-PET/MRI is at least equivalent to FDG-PET/CT and provides additional diagnostic benefits, such as higher\nsoft tissue resolution [27,36].\nMRI Abdomen and Pelvis Without and With IV Contrast\nMRI of the abdomen and pelvis may be useful in the posttreatment response evaluation of ovarian cancer [2]. MRI\nhas comparable sensitivity and specificity to CT scans [37,38].", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 5, "page_to": 5, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "74b4802eb8689cd6c06cabb65239ac6871094d41d10e3fdc374cbefa596819af"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000019", "text": "ACR Appropriateness Criteria®\n6\nStaging and Follow-up of Ovarian Cancer\nMRI Abdomen and Pelvis Without IV Contrast\nMRI of the abdomen and pelvis without IV contrast may be considered in the posttreatment response evaluation of\novarian cancer and may offer improved soft tissue contrast compared with CT without IV contrast.\nUS Abdomen and Pelvis Transabdominal\nThere is no relevant literature to support the use of transabdominal US of the abdomen and pelvis in evaluating\nposttreatment response.\nUS Pelvis Transvaginal\nThere is no relevant literature to support the use of transvaginal US of the pelvis for the evaluation of posttreatment\nresponse.\nVariant 3: Adult. Ovarian cancer. Posttreatment routine surveillance. Asymptomatic patient, no suspected\nrecurrence.\nThe goal of imaging is to identify disease recurrence in asymptomatic patients on surveillance with a history of\ntreated ovarian cancer. With the relevant imaging information, early and unexpected recurrence can be identified,\nthus improving patient outcomes.\nThe role for routine surveillance with imaging is unclear in patients considered to be in clinical remission. Imaging", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 6, "page_to": 6, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "63cf9085c25cbc29d7dbf5b90d036b5bef88b9b9b74034682df1268e9431c1be"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000020", "text": "thus improving patient outcomes.\nThe role for routine surveillance with imaging is unclear in patients considered to be in clinical remission. Imaging\nhas limited sensitivity for the detection of small tumor deposits in the abdomen and pelvis, with or without\nmonitoring of cancer antigen 125 (CA-125) levels [4,39]. NCCN guidelines for follow-up after primary treatment\nincludes scheduled clinical visits, imaging when clinically indicated (CT of the chest, abdomen, and pelvis; MRI;\nFDG-PET/CT; or PET), and CA-125 monitoring if initial elevation was present [2].\nSurveillance imaging may be warranted in asymptomatic patients under circumstances in which tumor markers are\ndeemed unreliable, physical examinations are inconclusive, or there is a significant risk of recurrence [2].\nThe patient population defined in this scenario is an asymptomatic patient in whom no recurrence is suspected (eg,\nno concerning physical examination findings and no elevation of serum tumor markers).\nCT Abdomen and Pelvis With IV Contrast\nThe use of surveillance with CT of the abdomen and pelvis with IV contrast is unclear in those patients considered", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 6, "page_to": 6, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "bb86f909349533824ec6ecc89e6234abd7b5022185e79c8a9ad9affd613ef8a1"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000021", "text": "CT Abdomen and Pelvis With IV Contrast\nThe use of surveillance with CT of the abdomen and pelvis with IV contrast is unclear in those patients considered\nto be in clinical remission. In one study with CT surveillance, a higher rate of optimal secondary cytoreductive\nsurgery and improved overall survival was reported in those with asymptomatic recurrences compared with patients\nwith symptomatic recurrences [38,40]. However, in another study of 412 patients, recurrence in 80% of the patient\npopulation was detected by either physical examination (15%), imaging (27%), CA-125 level (23%), or CA-125\nlevel combined with imaging (35%) [4,38]. In this same study, no difference in overall survival was shown between\nasymptomatic and symptomatic patients with recurrence.\nCT Abdomen and Pelvis Without and With IV Contrast\nThere is no relevant literature to support the use of CT of the abdomen and pelvis without and with IV contrast in\nasymptomatic patients without suspected recurrence.\nCT Abdomen and Pelvis Without IV Contrast\nIn instances for which CT of the abdomen and pelvis is clinically indicated, CT of the abdomen and pelvis without", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 6, "page_to": 6, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "b60ebfcc8015fd08f626f905361848a57501ffbd3998edeb41714d6d4fcb2d83"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000022", "text": "CT Abdomen and Pelvis Without IV Contrast\nIn instances for which CT of the abdomen and pelvis is clinically indicated, CT of the abdomen and pelvis without\nIV contrast may be considered in some clinical instances.\nCT Chest With IV Contrast\nSurveillance with CT of the chest with IV contrast is unclear in patients without suspected recurrence. Per NCCN\nguidelines, CT of the chest may be considered as part of monitoring and follow-up, as clinically useful [2].\nCT Chest Without and With IV Contrast\nThere is no relevant literature to support the use of CT of the chest without and with IV contrast in asymptomatic\npatients without suspected recurrence.\nCT Chest Without IV Contrast\nThe utility of surveillance imaging is unclear in those patients considered to be in clinical remission. Per NCCN\nguidelines, CT of the chest may be considered as part of monitoring and follow-up, as clinically indicated [2].\nFDG-PET/CT Skull Base to Mid-Thigh\nThe use of surveillance FDG-PET/CT is unclear in those patients considered to be in clinical remission. Per NCCN\nguidelines, PET/CT or PET may be considered as part of monitoring and follow-up, as clinically indicated [2].", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 6, "page_to": 6, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "93a32b133c013207496584a2feb54abcf5c32682c7c74d1894c71cef865741da"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000023", "text": "ACR Appropriateness Criteria®\n7\nStaging and Follow-up of Ovarian Cancer\nFDG-PET/MRI Skull Base to Mid-Thigh\nThere is no relevant literature to support the use of FDG-PET/MRI in asymptomatic patients without suspected\nrecurrence.\nMRI Abdomen and Pelvis Without and With IV Contrast\nPer NCCN guidelines, MRI may be considered as part of monitoring and follow-up for patients with ovarian cancer\nin the posttreatment routine surveillance setting, as clinically indicated [2]. As such, MRI of the abdomen without\nand with IV contrast may be useful.\nMRI Abdomen and Pelvis Without IV Contrast\nPer NCCN guidelines, MRI may be considered as part of monitoring and follow-up for patients with ovarian cancer\nin the posttreatment routine surveillance setting, as clinically indicated [2]. As such, MRI of the abdomen and pelvis\nwithout IV contrast may be useful.\nUS Abdomen and Pelvis Transabdominal\nThere is no evidence to support the use of transabdominal US of the abdomen and pelvis for posttreatment\nsurveillance in asymptomatic patients.\nUS Pelvis Transvaginal\nThere is no evidence to support the use of transvaginal US of the pelvis for posttreatment surveillance in", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 7, "page_to": 7, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "93be2c01cc1ba5e882e872c07c3083effc2ee735d5e882638c0746851446160b"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000024", "text": "surveillance in asymptomatic patients.\nUS Pelvis Transvaginal\nThere is no evidence to support the use of transvaginal US of the pelvis for posttreatment surveillance in\nasymptomatic patients with a history of treated ovarian cancer.\nVariant 4: Adult. Ovarian cancer. Posttreatment evaluation. Suspected or known recurrence.\nThe goal of imaging is to identify sites of disease recurrence in patients with a history of treated ovarian cancer with\nsuspected or known recurrence. The relevant imaging information can inform treatment planning and specifically\nguide decisions related to surgical or medical treatment.\nIn the evaluation for recurrence and extent of disease, imaging of the chest, abdomen, and pelvis plays a key role.\nThe suspicion of recurrence after treatment may arise from clinical symptoms, findings during physical\nexamination, or an increase in CA-125 levels, which would then prompt the need for imaging to evaluate for\nrecurrence.\nCT Abdomen and Pelvis With IV Contrast\nCT of the abdomen and pelvis with IV and oral contrast is the most useful procedure for confirming recurrent", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 7, "page_to": 7, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "1c9e44288b9f4519db1b1e9d211ddf7df843c02e37d907d74b6dea607dcfc576"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000025", "text": "recurrence.\nCT Abdomen and Pelvis With IV Contrast\nCT of the abdomen and pelvis with IV and oral contrast is the most useful procedure for confirming recurrent\ndisease and determining the extent in patients with suspected or known recurrence (based on clinical symptoms,\nphysical examination, or CA-125 level) [38]. Contrast-enhanced CT has a reported sensitivity ranging from 58% to\n84% and a specificity in the range of 59% to 100% in identifying tumor recurrence [41-43]. Recurrent disease often\npresents as peritoneal implants, both within the peritoneal cavity and along the surface of visceral organs. A\nlimitation with CT is detecting peritoneal, mesenteric, or serosal lesions that are <5 mm in size [40].\nCT Abdomen and Pelvis Without and With IV Contrast\nThere is no relevant literature to support the use of CT of the abdomen and pelvis without and with IV contrast in\nthe evaluation of suspected or known ovarian cancer recurrence.\nCT Abdomen and Pelvis Without IV Contrast\nCT of the abdomen and pelvis without IV contrast offers limited ability to identify small peritoneal or mesenteric\nimplants, or lymphadenopathy among bowel loops and other adjacent organs.", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 7, "page_to": 7, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "c285d9433736b70195c7f70e196b277c220a9d4e259b132a5502f6771a0dcd3d"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000026", "text": "CT of the abdomen and pelvis without IV contrast offers limited ability to identify small peritoneal or mesenteric\nimplants, or lymphadenopathy among bowel loops and other adjacent organs.\nCT Chest With IV Contrast\nCT of the chest with IV contrast is the most useful modality in evaluating recurrent or metastatic disease in the\nthorax.\nCT Chest Without and With IV Contrast\nThere is no relevant literature to support the use of CT of the chest without and with IV contrast in the evaluation\nof suspected or known ovarian cancer recurrence.\nCT Chest Without IV Contrast\nCT of the chest without IV contrast is not typically useful in this setting.\nFDG-PET/CT Skull Base to Mid-Thigh\nFDG-PET/CT can be used in the evaluation of recurrent ovarian cancer [2]. In a recent meta-analysis, FDG-PET/CT\nshowed a sensitivity of 88% and a specificity of 89% in diagnosing recurrent epithelial ovarian cancer [44]. FDG-", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 7, "page_to": 7, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "3d412f0483b2d017bd7669ec9f8fcc6f769580938b97b4677d0837ef269a5aa8"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000027", "text": "ACR Appropriateness Criteria®\n8\nStaging and Follow-up of Ovarian Cancer\nPET/CT can also be used as an adjunct imaging study when there is a high clinical suspicion for recurrence but CT\nis indeterminate [45]. Certain limitations of FDG-PET/CT including poor detection of subcentimeter metastases\ndue to suboptimal spatial resolution of PET, high concentration of excreted FDG obscuring lesions near the bladder,\nand metabolic activity on or between bowel loops, particularly after surgery when adhesions or inflammation are\npresent, may be difficult to assess [44,45].\nFDG-PET/MRI Skull Base to Mid-Thigh\nIn specific patient scenarios, FDG-PET/MRI may be useful in the suspected recurrence. Example scenarios include\nthose patients with high clinical suspicion (such as rising CA-125 levels or worsening clinical symptoms) but\nindeterminate CT findings [27].\nMRI Abdomen and Pelvis Without and With IV Contrast\nMRI of the abdomen and pelvis may be useful as a problem-solving tool in those patients with suspected or known\ndisease recurrence and when CT is indeterminate.\nMRI Abdomen and Pelvis Without IV Contrast", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 8, "page_to": 8, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "67c059251eef99fd2463b9aa8891f70128a8d9d565845bf8ff07000396c3272b"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000028", "text": "disease recurrence and when CT is indeterminate.\nMRI Abdomen and Pelvis Without IV Contrast\nMRI without IV contrast may be considered in those patients with suspected or known disease recurrence of ovarian\ncancer and when CT is indeterminate. However, IV contrast is preferable for the detection and characterization of\nlesions suspected to represent tumor deposits.\nUS Abdomen and Pelvis Transabdominal\nThere is no relevant literature to support the use of transabdominal US of the abdomen and pelvis in the evaluation\nof suspected or known ovarian cancer recurrence.\nUS Pelvis Transvaginal\nThere is no relevant literature to support the routine use of pelvic US in the evaluation of suspected or known\novarian cancer recurrence following treatment.\nSummary of Highlights\nThis is a summary of the key recommendations from the variant tables. Refer to the complete narrative document\nfor more information.\n•\nVariant 1: For initial pretreatment staging of ovarian cancer, CT abdomen and pelvis with IV contrast and CT\nchest with IV contrast are recommended complementary studies to stage the tumor and evaluate for distant", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 8, "page_to": 8, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "68b8ae1474289609881921987160323488f181af2ab3a695379e8d23dabfa4c0"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000029", "text": "chest with IV contrast are recommended complementary studies to stage the tumor and evaluate for distant\nmetastases. MRI abdomen and pelvis without and with IV contrast, MRI abdomen and pelvis without IV\ncontrast, CT abdomen and pelvis without IV contrast, CT chest without IV contrast, FDG-PET/MRI, and FDG-\nPET/CT may be appropriate in staging ovarian cancer prior to treatment.\n•\nVariant 2: For follow-up imaging evaluation following treatment for ovarian cancer, CT abdomen and pelvis\nwith IV contrast, CT chest with IV contrast, and FDG-PET/CT are recommended complementary studies to\nevaluate the posttreatment response. MRI abdomen and pelvis without and with IV contrast, MRI abdomen and\npelvis without IV contrast, CT abdomen and pelvis without IV contrast, CT chest without IV contrast, and FDG-\nPET/MRI may be appropriate in the posttreatment response evaluation.\n•\nVariant 3: For posttreatment imaging evaluation in asymptomatic patients without suspected recurrence, the\nrole of imaging is unclear in those patients considered to be in clinical remission. CT abdomen and pelvis with", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 8, "page_to": 8, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "6e7190488dadfe9903a04f6da8125576f08e55198e7290e0ea735e56a5c32235"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000030", "text": "role of imaging is unclear in those patients considered to be in clinical remission. CT abdomen and pelvis with\nor without IV contrast, CT chest with or without IV contrast, MRI abdomen and pelvis without and with IV\ncontrast, MR abdomen and pelvis without IV contrast, FDG-PET/MRI, and FDG-PET/CT may be appropriate,\nas clinically indicated.\n•\nVariant 4: For follow-up imaging evaluation following treatment for ovarian cancer in patients with suspected\nor known recurrence, CT abdomen and pelvis with IV contrast, CT chest with IV contrast, and FDG-PET/CT\nare recommended complementary studies to evaluate for local recurrence and metastatic disease. MRI abdomen\nand pelvis without and with IV contrast, MRI abdomen and pelvis without IV contrast, CT abdomen and pelvis\nwithout IV contrast, CT chest without IV contrast, and FDG-PET/MRI may be appropriate in the posttreatment\nevaluation of patients with suspected or known recurrence.", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 8, "page_to": 8, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "0a7d7ad40235c7152f7f9e75524c0809c9bd32281c251f093cadaf39fa17cf65"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000031", "text": "ACR Appropriateness Criteria®\n9\nStaging and Follow-up of Ovarian Cancer\nSupporting Documents\nThe evidence table, literature search, and appendix for this topic are available at https://acsearch.acr.org/list. The\nappendix includes the strength of evidence assessment and the final rating round tabulations for each\nrecommendation.\nFor additional information on the Appropriateness Criteria methodology and other supporting documents, click\nhere.\nGender Equality and Inclusivity Clause\nThe ACR acknowledges the limitations in applying inclusive language when citing research studies that pre-dates\nthe use of the current understanding of language inclusive of diversity in sex, intersex, gender and gender-diverse\npeople. The data variables regarding sex and gender used in the cited literature will not be changed. However, this\nguideline will use the terminology and definitions as proposed by the National Institutes of Health [46].\nAppropriateness Category Names and Definitions\nAppropriateness Category Name\nAppropriateness\nRating\nAppropriateness Category Definition\nUsually Appropriate\n7, 8, or 9\nThe imaging procedure or treatment is indicated in the", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 9, "page_to": 9, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "933002d5a048990984b574c6875e8983df41f3e9dafdacb22a7e867cd8efa95a"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000032", "text": "Appropriateness Category Name\nAppropriateness\nRating\nAppropriateness Category Definition\nUsually Appropriate\n7, 8, or 9\nThe imaging procedure or treatment is indicated in the\nspecified clinical scenarios at a favorable risk-benefit\nratio for patients.\nMay Be Appropriate\n4, 5, or 6\nThe imaging procedure or treatment may be indicated\nin the specified clinical scenarios as an alternative to\nimaging procedures or treatments with a more\nfavorable risk-benefit ratio, or the risk-benefit ratio for\npatients is equivocal.\nMay Be Appropriate\n(Disagreement)\n5\nThe individual ratings are too dispersed from the panel\nmedian. The different label provides transparency\nregarding the panel’s recommendation. “May be\nappropriate” is the rating category and a rating of 5 is\nassigned.\nUsually Not Appropriate\n1, 2, or 3\nThe imaging procedure or treatment is unlikely to be\nindicated in the specified clinical scenarios, or the\nrisk-benefit ratio for patients is likely to be\nunfavorable.\nRelative Radiation Level Information\nPotential adverse health effects associated with radiation exposure are an important factor to consider when", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 9, "page_to": 9, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "cbc0bbde189614db5050563e59019b59da492ef6a423b7739e2ec161979d29f0"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000033", "text": "unfavorable.\nRelative Radiation Level Information\nPotential adverse health effects associated with radiation exposure are an important factor to consider when\nselecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with\ndifferent diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging\nexamination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate\npopulation total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at\ninherently higher risk from exposure, because of both organ sensitivity and longer life expectancy (relevant to the\nlong latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for\npediatric examinations are lower as compared with those specified for adults (see Table below). Additional\ninformation regarding radiation dose assessment for imaging examinations can be found in the ACR\nAppropriateness Criteria® Radiation Dose Assessment Introduction document [47].", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 9, "page_to": 9, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "6e8cc917dfdbd123843105bb260eb5936d42175d1dc3b50f5eeaa3f3884843d9"}
{"doc_id": "acr_appropriateness_criteria__v00000000", "chunk_id": "000034", "text": "ACR Appropriateness Criteria®\n10\nStaging and Follow-up of Ovarian Cancer\nRelative Radiation Level Designations\nRelative Radiation Level*\nAdult Effective Dose Estimate\nRange\nPediatric Effective Dose Estimate\nRange\nO\n0 mSv\n0 mSv\n☢\n<0.1 mSv\n<0.03 mSv\n☢☢\n0.1-1 mSv\n0.03-0.3 mSv\n☢☢☢\n1-10 mSv\n0.3-3 mSv\n☢☢☢☢\n10-30 mSv\n3-10 mSv\n☢☢☢☢☢\n30-100 mSv\n10-30 mSv\n*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary\nas a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used).\nThe RRLs for these examinations are designated as “Varies.”", "section": "Staging and Follow-up of Ovarian Cancer", "page_from": 10, "page_to": 10, "display_name": "ACR Appropriateness Criteria", "version": "v00000000", "created_at": "2025-11-28T06:02:12", "hash": "2f4e6a96a3b161ed0da394ec70d5c0a0543ae12748d8974cfd2ce8af4c339f7f"}
